Brief: Hyphens Pharma International Inks Exclusive Licensing Deal Of Ustekinumab Biosimilar
14/12/2021 08:18
Dec 14 (Reuters) - Hyphens Pharma International HYPH.SI :
* HYPHENS PHARMA HAS INKED EXCLUSIVE LICENSING DEAL OF
USTEKINUMAB
BIOSIMILAR
* UNIT SIGNED AN EXCLUSIVE LICENSE AND SUPPLY AGREEMENT WITH
DKSH'S SUBSIDIARY FAVOREX
* AGREEMENT TO COMMERCIALISE USTEKINUMAB BIOSIMILAR PRODUCED
BY
ALVOTECH HF IN SINGAPORE, MALAYSIA, AND PHILIPPINES
Source text for Eikon: ID:nSN52nxJK
Further company coverage: HYPH.SI
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hyphens Pharma International
See all newsSingapore's Hyphens Pharma half-year profit jumps as margins improve
Brief: Hyphens Pharma International Updates On Cerapro® Med Skin Barrier Cream
Brief: Hyphens Pharma International Says Unit Gets Exclusive Rights To Commercialise Metoject
Brief: Hyphens Pharma International Posts FY Net Income Of SGD 10.9 Million
Brief: Hyphens Pharma International Licenses Amenalief From Maruho For ASEAN